Market Place
Sourcing Support
Seastar Medical Reveals Positive QUELIMMUNE SAVE Registry Data
30 Mar 2026 //
GLOBENEWSWIRE
Seastar Medical Reveals 2025 Financials And Business Updates
25 Mar 2026 //
GLOBENEWSWIRE
Seastar Medical To Release 2025 Q4 And Year-End Financials
18 Mar 2026 //
GLOBENEWSWIRE
Seastar Medical To Present At Noble Capital Markets Conference
29 Jan 2026 //
GLOBENEWSWIRE
Seastar Medical Announces 1-For-10 Reverse Split
23 Dec 2025 //
GLOBENEWSWIRE
Seastar Medical To Present At NobleCon21 Investor Conference
20 Nov 2025 //
GLOBENEWSWIRE
Seastar Medical Announces Appointment of Michael Messinger as CFO
17 Nov 2025 //
GLOBENEWSWIRE
Seastar Medical Reveals Q3 2025 Financials And Business Updates
13 Nov 2025 //
GLOBENEWSWIRE
Seastar Medical To Release Q3 Financial Results On Nov 13, 2025
05 Nov 2025 //
GLOBENEWSWIRE
SeaStar Early Positive Data for QUELIMMUNE in Pediatric AKI
29 Sep 2025 //
GLOBENEWSWIRE
Seastar Medical to Join HC Wainwright Global Investment Conf
04 Sep 2025 //
GLOBENEWSWIRE
SeaStar Medical`s Q2 2025 Financial Results and Business Updates
13 Aug 2025 //
GLOBENEWSWIRE
SeaStar Medical to Report Q2 Financial Results on August 13, 2025
07 Aug 2025 //
GLOBENEWSWIRE
SeaStar Medical Expands QUELIMMUNE Registry, Grows Customer Base
16 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Announces Positive Nasdaq Listing Determination
02 Jul 2025 //
GLOBENEWSWIRE
SeaStar Medical Reports Update on Nasdaq Listing Status
25 Jun 2025 //
GLOBENEWSWIRE
SeaStar Highlights QUELIMMUNE Adoption, Patient Story
24 Jun 2025 //
GLOBENEWSWIRE
SeaStar Medical Announces $8M Public Offering Price
20 Jun 2025 //
GLOBENEWSWIRE
AREVA Institute, SeaStar Medical Win DoD Grant for SCD Therapy
11 Jun 2025 //
GLOBENEWSWIRE
SeaStar CMS Coverage For SCD Trial In Cardiorenal Patients
28 May 2025 //
GLOBENEWSWIRE
SeaStar Medical Reports Q1 2025 Financial Results & Updates
14 May 2025 //
GLOBENEWSWIRE
SeaStar Medical to Report Q1 Financial Results on May 14, 2025
07 May 2025 //
GLOBENEWSWIRE
SeaStar Medical CEO Interview on Benzinga All Access Today
30 Apr 2025 //
GLOBENEWSWIRE
SeaStar Medical Reports Q4 and Full Year 2024 Financial Results
27 Mar 2025 //
GLOBENEWSWIRE
SeaStar Medical to Report Q4 and Year-End 2024 Results on March 2
24 Mar 2025 //
GLOBENEWSWIRE
SeaStar Medical Closes $6M Registered Direct Offering
03 Feb 2025 //
GLOBENEWSWIRE
SeaStar Announces 6M Registered Direct Offering Priced At Market
31 Jan 2025 //
GLOBENEWSWIRE
SeaStar Activates 15th Site For Acute Kidney Injury Pivotal Trial
22 Jan 2025 //
GLOBENEWSWIRE
FDA Approves Study Of Seastar Device For Cardiorenal Syndrome
13 Jan 2025 //
GLOBENEWSWIRE
SeaStar Medical to Hold Business Update Call on Dec 11
04 Dec 2024 //
GLOBENEWSWIRE
SeaStar Medical to Present at NobleCon20 on December 4, 2024
26 Nov 2024 //
GLOBENEWSWIRE
ISS & Glass Lewis Support SeaStar Medical’s Share Issuance Proposals
22 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Reports Q3 2024 Financial Results & Business Update
13 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Achieves Record Enrollment in Adult AKI Trial
01 Nov 2024 //
GLOBENEWSWIRE
SeaStar Medical Enrolls Subjects in AKI Pivotal Trial
23 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical Enrollment In AKI Trial Exceeds Halfway Point
18 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical Showcases New Data On Immunomodulatory Device
15 Oct 2024 //
GLOBENEWSWIRE
SeaStar Medical To Webcast Fireside Chat At Wainwright Conference
05 Sep 2024 //
GLOBENEWSWIRE
SeaStar Medical Reports Q2 2024 Results And Provides Business Update
13 Aug 2024 //
GLOBENEWSWIRE
First Pediatric Patient Treated With SeaStar`s QUELIMMUNE Device
23 Jul 2024 //
GLOBENEWSWIRE
CMS Grants Coverage For SeaStar Medical`s AKI Device Pivotal Trial
16 Jul 2024 //
GLOBENEWSWIRE
SeaStar Medical Ships First Quelimmune Product Order to U.S. Distribution
12 Jul 2024 //
GLOBENEWSWIRE
SeaStar Medical Closes $10 Million Registered Direct Offering
11 Jul 2024 //
GLOBENEWSWIRE
SeaStar Medical Announces $10M Registered Direct Offering
10 Jul 2024 //
GLOBENEWSWIRE
SeaStar Medical Finalizes FDA Labeling For QUELIMMUNE Ahead Of Sales
03 Jul 2024 //
GLOBENEWSWIRE
SeaStar Medical’s Cytopheretic Device Featured in Two PPT at the 42nd Vicenza
11 Jun 2024 //
GLOBENEWSWIRE
SeaStar Medical Strengthens Board, Transitions To Commercial Stage
10 Jun 2024 //
GLOBENEWSWIRE
Nature Paper Details SeaStar`s Inflammation Control Mechanism
07 Jun 2024 //
GLOBENEWSWIRE
SeaStar Medical Announces 25-for-1 Reverse Stock Split
06 Jun 2024 //
GLOBENEWSWIRE
SeaStar Medical To Present At Virtual Growth Conference June 12
06 Jun 2024 //
GLOBENEWSWIRE
SeaStar Medical Reports Q1 2024 Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
SeaStar: $3.6M NIH Grant For Cytopheretic Device In Heart Failure Study
30 Apr 2024 //
GLOBENEWSWIRE
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
17 Apr 2024 //
GLOBENEWSWIRE
SeaStar Medical At Noble Emerging Growth Healthcare Conference
11 Apr 2024 //
GLOBENEWSWIRE
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
27 Mar 2024 //
GLOBENEWSWIRE
SeaStar Medical Provides Updates on Commercial Launch of Quelimmune
12 Mar 2024 //
GLOBENEWSWIRE
SeaStar Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury
11 Mar 2024 //
GLOBENEWSWIRE
Manuscript Discussing Benefit of SeaStar Medical™s Selective Cytopheretic Device
27 Feb 2024 //
GLOBENEWSWIRE
FDA Grants Device Exemption Approval to SeaStar`s Cytopheretic Device
22 Feb 2024 //
GLOBENEWSWIRE
SeaStar Granted Patent Covering the Selective Cytopheretic Device Technology
01 Feb 2024 //
GLOBENEWSWIRE
